• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CAPSAICIN Drug Record

  • Summary
  • Interactions
  • Claims
  • CAPSAICIN chembl:CHEMBL294199 Approved

    Alternate Names:

    ZOSTRIX
    QUTENZA
    FEMA NO. 3404
    CAPSAICIN
    ZACIN
    ZOSTRIX HP
    NGX-1998
    ALGRX 4975
    ALGRX-4975
    NSC-56353
    NGX-4010
    QUTENZA®
    ISODECENOIC ACID VANILLYLAMIDE
    TRANS-8-METHYL-N-VANILLYL-6-NONENAMIDE
    (E)-8-METHYL-N-VANILLYL-6-NONENAMIDE
    chembl:CHEMBL294199
    chemidplus:404-86-4
    drugbank:06774
    pubchem.compound:1548943
    rxcui:1992

    Drug Info:

    Drug Categories polyunsaturated alkamides
    Drug Categories fatty acids, unsaturated
    FDA Approval approved
    FDA Approval not approved (orphan status)
    Drug Class Small molecule
    Drug Indications analgesic
    Drug Categories basic lotions and liniments
    Drug Categories capsaicin and similar agents
    Drug Categories capsaicin, antagonists & inhibitors
    Drug Categories cholinesterase inhibitors
    Drug Categories cytochrome p-450 cyp1a2 inducers (strength unknown)
    Drug Categories cytochrome p-450 cyp1a2 substrates
    Drug Categories cytochrome p-450 cyp3a4 inhibitors
    Drug Categories cytochrome p-450 cyp3a4 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 enzyme inducers
    Drug Categories cytochrome p-450 enzyme inhibitors
    Drug Categories cytochrome p-450 substrates
    Drug Categories dermatologicals
    Drug Categories monoamine oxidase a inhibitors for interaction with monoamine oxidase a substrates
    Drug Categories musculo-skeletal system
    Drug Categories topical products for joint and muscular pain
    (4 More Sources)

    Publications:

    Mannion et al., 1999, Neurotrophins: peripherally and centrally acting modulators of tactile stimulus-induced inflammatory pain hypersensitivity., Proc. Natl. Acad. Sci. U.S.A.
    Reilly et al., 2003, Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells., Chem. Res. Toxicol.
    Oikawa et al., 2006, Mechanism of oxidative DNA damage induced by capsaicin, a principal ingredient of hot chili pepper., Free Radic. Res.
    Suzuki et al., 1985, Regional distribution of a novel pituitary protein (7B2) in the rat spinal cord: effect of neonatal capsaicin treatment and thoracic cord transection., Neurosci. Lett.
    Anand et al., 2011, Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch., Br J Anaesth
    Wallace et al., 2011, Qutenza®: a capsaicin 8% patch for the management of postherpetic neuralgia., Expert Rev Neurother
    Joung et al., 2007, Capsaicin induces heme oxygenase-1 expression in HepG2 cells via activation of PI3K-Nrf2 signaling: NAD(P)H:quinone oxidoreductase as a potential target., Antioxid. Redox Signal.
    Malcangio et al., 2000, Intrathecally injected neurotrophins and the release of substance P from the rat isolated spinal cord., Eur. J. Neurosci.
    Lee et al., 2007, Capsaicin promotes the development of burst-forming units--erythroid (BFU-E) from mouse bone marrow cells., Exp. Mol. Med.
    Kim et al., 1997, Proliferation and repair of guinea pig tracheal epithelium after neuropeptide depletion and injury in vivo., Am. J. Physiol.
    Sharkey et al., 1999, Immediate-early gene expression in the inferior mesenteric ganglion and colonic myenteric plexus of the guinea pig., J. Neurosci.
    Knight et al., 1997, Localization of leukaemia inhibitory factor to airway epithelium and its amplification of contractile responses to tachykinins., Br. J. Pharmacol.
    Sweeney et al., 1989, Morphine, capsaicin and K+ release purines from capsaicin-sensitive primary afferent nerve terminals in the spinal cord., J. Pharmacol. Exp. Ther.
    Okere et al., 2004, Capsaicin increases GFAP and glutamine synthetase immunoreactivity in rat arcuate nucleus and median eminence., Neuroreport
    Han et al., 2006, Effects of capsaicin on P-gp function and expression in Caco-2 cells., Biochem. Pharmacol.
    Kuramori C et al., 2009, Capsaicin binds to prohibitin 2 and displaces it from the mitochondria to the nucleus., Biochem Biophys Res Commun
  • CAPSAICIN   SCG5

    Interaction Score: 6.68

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3858706


    Sources:
    NCI

  • CAPSAICIN   RNASEH2A

    Interaction Score: 3.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10087087


    Sources:
    NCI

  • CAPSAICIN   PHB2

    Interaction Score: 2.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19116139


    Sources:
    DrugBank

  • CAPSAICIN   PCNA

    Interaction Score: 1.67

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9435579


    Sources:
    NCI

  • CAPSAICIN   EPOR

    Interaction Score: 0.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17603282


    Sources:
    NCI

  • CAPSAICIN   LIF

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9138695


    Sources:
    NCI

  • CAPSAICIN   TRPV1

    Interaction Score: 0.5

    Interaction Types & Directionality:
    activator (activating)
    agonist (activating)

    Interaction Info:
    Trial Name Adlea
    Novel drug target Established target
    Trial Name Transacin

    PMIDs:
    21852280 21158551


    Sources:
    DTC TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

  • CAPSAICIN   NT5E

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2492344


    Sources:
    NCI

  • CAPSAICIN   NTF3

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10651868


    Sources:
    NCI

  • CAPSAICIN   GFAP

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15076747


    Sources:
    NCI

  • CAPSAICIN   CFTR

    Interaction Score: 0.11

    Interaction Types & Directionality:
    activator (activating)

    Interaction Info:
    Specific Action of the Ligand Potentiation
    Endogenous Drug? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • CAPSAICIN   BDNF

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10430952


    Sources:
    NCI

  • CAPSAICIN   ABCB1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16674925


    Sources:
    NCI

  • CAPSAICIN   CYP1A2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12641434 17015277


    Sources:
    NCI

  • CAPSAICIN   NFE2L2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17979524


    Sources:
    NCI DTC

  • CAPSAICIN   ALDH1A1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CAPSAICIN   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DrugBank: DB06774

    • Version: 5.1.7

    Alternate Names:
    CAPSAICIN DrugBank Drug Name
    404-86-4 CAS Number
    1st Medxpatch With Lidocaine 4% Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Categories alkaloids

    Publications:
    Kuramori C et al., 2009, Capsaicin binds to prohibitin 2 and displaces it from the mitochondria to the nucleus., Biochem Biophys Res Commun
    Anand et al., 2011, Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch., Br J Anaesth
    Wallace et al., 2011, Qutenza®: a capsaicin 8% patch for the management of postherpetic neuralgia., Expert Rev Neurother

  • TdgClinicalTrial: CAPSAICIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications analgesic
    Drug Class Small molecule
    FDA Approval not approved (orphan status)

    Publications:

  • NCI: CAPSAICIN

    • Version: 14-September-2017

    Alternate Names:
    C339 NCI drug code

    Drug Info:

    Publications:
    Mannion et al., 1999, Neurotrophins: peripherally and centrally acting modulators of tactile stimulus-induced inflammatory pain hypersensitivity., Proc. Natl. Acad. Sci. U.S.A.
    Han et al., 2006, Effects of capsaicin on P-gp function and expression in Caco-2 cells., Biochem. Pharmacol.
    Malcangio et al., 2000, Intrathecally injected neurotrophins and the release of substance P from the rat isolated spinal cord., Eur. J. Neurosci.

  • DTC: CAPSAICIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL294199 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Capsaicin

    • Version: 2020.06.01

    Alternate Names:
    D0U5CE TTD Drug ID

    Drug Info:

    Publications:

  • GuideToPharmacology: 53801090

    • Version: 29-September-2020

    Alternate Names:
    CAPSAICIN GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL294199

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL294199

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21